Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up To 56%
Upstream Bio (NASDAQ:UPB) announced positive top-line results from its Phase II VALIANT trial for verekitug, a treatment for severe asthma. The trial met its primary endpoint, showing statistically significant reductions in annualized asthma exacerbation rates, with the 100 mg every 12 weeks regimen achieving a 56% reduction. Additionally, two dosing regimens demonstrated clinically meaningful improvements in lung function and reductions in a key inflammatory biomarker (FeNO), and verekitug was generally well-tolerated.
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%
Upstream Bio recently released positive top-line results from its Phase II VALIANT trial for verekitug in severe asthma, showing a statistically significant reduction in annualized asthma exacerbation rates, with up to a 56% reduction. The study also demonstrated clinically meaningful improvements in lung function and reductions in FeNO, a biomarker for airway inflammation. The company plans an integrated analysis with data from another study for dose optimization and aims to begin parallel Phase III trials for severe asthma and chronic rhinosinusitis with nasal polyps.
Upstream Bio down despite mid-stage trial win for asthma drug
Upstream Bio's stock fell despite announcing positive mid-stage trial results for its asthma drug, UPB-101. The drug met all primary and secondary endpoints in patients with moderate to severe asthma, showing significant improvement in lung function and inflammation biomarkers. This suggests potential for UPB-101 to be a best-in-class treatment for asthma.
Upstream Bio (NASDAQ:UPB) Sees Large Volume Increase - Here's Why
Upstream Bio (NASDAQ:UPB) experienced a significant trading volume increase of 114% on Friday, with 2,234,547 shares traded, pushing the stock to $9.8690 after a previous close of $12.80. The clinical-stage biotech company, focused on viral vector vaccines and immuno-oncology, holds a "Moderate Buy" consensus rating from analysts, with price targets ranging from $40 to $45.25. Despite a negative P/E ratio, hedge funds have shown increased activity, with several institutional investors adjusting their positions in the company.
Upstream Bio Phase 2 VALIANT Study Meets Primary Endpoint, But Stock Slides In Pre-market
Upstream Bio announced that its Phase 2 VALIANT study for verekitug in severe asthma met its primary endpoint, showing significant reductions in asthma exacerbations and improved lung function. Despite these positive clinical trial results, the company's stock experienced a pre-market decline of over 30%. Upstream Bio plans to advance verekitug to Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps.
Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma
Upstream Bio will host a webcast on Wednesday, February 11, 2026, at 8:00 a.m. ET to announce top-line results from its Phase 2 VALIANT trial for verekitug. This trial evaluated the safety and efficacy of verekitug, an antagonist of the TSLP receptor, in 478 patients with severe asthma over a period of up to 60 weeks. The company, focused on inflammatory diseases, is also developing verekitug for chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio (NASDAQ:UPB) shares dropped significantly following clinical trial developments for its asthma treatment, despite the VALIANT trial demonstrating a 56% reduction in asthma attacks. An analyst from William Blair suggested the selloff might be "overdone," though concerns remain about the drug's competitive positioning due to varied efficacy at different dosing levels. The stock exhibits strong short-term momentum but shows mixed signals from RSI and MACD, with analysts maintaining a "Strong Buy" consensus.
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio's shares plunged over 54% following clinical trial results for its asthma treatment, verekitug, despite showing a 56% reduction in asthma attacks in the VALIANT trial. An analyst suggests the selloff is "overdone," but raises concerns about the drug's competitive positioning due to varied efficacy between dosing regimens. Despite the stock's recent decline, it shows strong short-term momentum and carries a "Strong Buy" rating with an average price forecast of $49.00.
Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns
Upstream Bio Inc. (NASDAQ: UPB) shares have experienced a significant selloff following recent developments in its clinical trials for an asthma treatment, despite positive results from its VALIANT trial. An analyst suggests the decline might be "overdone" given the trial's strong biomarker results, but raises concerns about the competitive positioning of their drug, verekitug, compared to others in development. The stock shows strong short-term momentum but mixed overall momentum indicators, though analysts maintain a Strong Buy rating with an average target price of $49.00.
Upstream Bio down despite mid-stage trial win for asthma drug
Upstream Bio's stock fell despite announcing positive results from a mid-stage trial for its asthma drug, UPB-101. The drug met its primary and secondary endpoints, showing significant improvement in lung function and inflammation biomarkers in patients with severe asthma. Despite the clinical success, the stock's decline suggests that investor expectations for the trial results may have been higher.
Upstream Bio (NASDAQ:UPB) Trading Down 10.3% - Time to Sell?
Upstream Bio's (NASDAQ:UPB) shares dropped 10.3% on Thursday, trading at $13.1760 with lower-than-average volume. The stock is significantly below its 50-day and 200-day moving averages, despite a "Moderate Buy" consensus rating from analysts with an average price target of $45.25. Several institutional investors like Norges Bank and UBS Group AG increased their holdings in Q4, indicating continued institutional interest.
Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data (UPB)
Upstream Bio, Inc. has been downgraded to a Hold rating despite positive Phase 2 VALIANT results for its drug Verekitug in severe asthma, which showed a significant reduction in annualized asthma exacerbation rate (AAER). While Verekitug offers competitive dosing, it faces increasing competition from other companies developing long-acting anti-TSLP antibodies. The company remains well-capitalized through 2027, but its future value will be heavily influenced by rival clinical data and regulatory outcomes for its own Phase 3 advancement.
Why Did UPB Stock Plunge 40% Today?
Shares of Upstream Bio Inc. (UPB) plummeted over 40% despite announcing positive top-line results from its Phase 2 VALIANT trial for Verekitug in severe asthma. The trial showed significant reductions in asthma attacks and good tolerability, leading the company to plan for Phase 3 studies. Stocktwits users expressed surprise at the market reaction, with many viewing the sharp decline as a buying opportunity.
Upstream To Upgrade Verekitug To Phase III After Positive Asthma Results
Upstream Bio is planning to advance its Verekitug drug to an investigational Phase III clinical trial. This decision follows positive results observed in earlier phases for the treatment of asthma. The company is poised to further develop this therapy for respiratory conditions.
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Upstream Bio announced positive top-line results from its Phase 2 VALIANT clinical trial for verekitug, targeting severe asthma. The trial met its primary endpoint, showing statistically significant reductions in annualized asthma exacerbation rates and clinically meaningful improvements in lung function and exhaled nitric oxide. Verekitug was well-tolerated, and the company plans to advance it into Phase 3 trials for severe asthma and CRSwNP.
Upstream Bio to report verekitug phase 2 trial results for severe asthma
Upstream Bio is set to release top-line results from its Phase 2 VALIANT trial for verekitug, a severe asthma treatment, on Wednesday at 8:00 a.m. ET. The company's stock has seen significant annual growth despite a recent weekly decline, and Mizuho has initiated coverage with an Outperform rating, anticipating positive Phase II results early in 2026. Verekitug targets the TSLP receptor and is also being developed for chronic rhinosinusitis with nasal polyps and COPD.
Upstream Bio (NASDAQ:UPB) Shares Gap Down - Here's Why
Upstream Bio (NASDAQ:UPB) shares gapped down significantly, opening at $19.00 after closing at $27.81, and later trading around $14.77, representing a roughly 46.2% intraday drop. The clinical-stage biotech company has a "Moderate Buy" consensus rating from analysts with an average price target of $45.25. Several hedge funds have recently adjusted their holdings in UPB.
Upstream Bio Reports Positive Phase 2 Verekitug Asthma Results
Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma, meeting the primary endpoint with significant reductions in exacerbation rates. The therapy also showed improved lung function and a consistent safety profile. These results support Upstream Bio's strategy to develop verekitug as a differentiated TSLP receptor antagonist for various severe respiratory indications, with funding secured through 2027.
Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data
Upstream Bio shares surged 15% pre-market following positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma. This data de-risks their lead asset, increasing the probability of regulatory approval in a multi-billion dollar market. Investors are now watching to see if the stock can maintain these gains, with a critical pivot point identified at $30.00.
Upstream Bio, Inc. Reports Positive Phase 2 VALIANT Trial Results for Verekitug
Upstream Bio, Inc. announced positive top-line results from its Phase 2 VALIANT trial for verekitug, targeting severe asthma. The drug significantly reduced asthma exacerbation rates, improved lung function, and suppressed exhaled nitric oxide. Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and CRSwNP.
Severe asthma trial: experimental drug cuts attacks up to 56%
Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma, showing significant reductions in annualized asthma exacerbation rates (AAER) by up to 56%. The experimental drug also improved lung function and reduced FeNO, proving generally well tolerated. Upstream Bio plans to advance verekitug into Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) following regulatory interactions.
Upstream Bio Shares Plunge 52% Despite Positive Phase 2 Asthma Data
Upstream Bio's shares plunged 52% despite the company announcing positive top-line results from its Phase 2 VALIANT clinical trial for verekitug in severe asthma. The stock tumbled following the news, with significant trading volume, indicating strong market reaction even as the trial assessing the safety and efficacy of verekitug showed positive outcomes.
Upstream Bio To Present Phase 2 VALIANT Trial Results In Severe Asthma, Today
Upstream Bio (UPB) is scheduled to present top-line results today from its Phase 2 VALIANT trial for Verekitug, a potential treatment for severe asthma. The trial investigated Verekitug's efficacy and safety, with participant enrollment completed in June 2025, paving the way for Phase 3 development. The company also highlighted positive Phase 2 results for Verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP) and its sustained financial position to fund operations through 2027.
Upstream Bio Stock Pre-Market (+15%) : Positive Phase 2 Asthma Trial Data
Upstream Bio's stock experienced a significant 15% pre-market increase following positive data from its Phase 2 asthma trial. The article indicates this positive development in the company's clinical research.
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
Upstream Bio announced positive top-line results from its Phase 2 VALIANT trial for verekitug in severe asthma, showing a significant reduction in asthma exacerbation rates and improved lung function. The drug was well-tolerated, and over 90% of eligible patients enrolled in a long-term extension study. The company plans to advance verekitug into Phase 3 trials for severe asthma and CRSwNP following regulatory interactions.
Upstream Bio to report verekitug phase 2 trial results for severe asthma
Upstream Bio (NASDAQ: UPB) will announce top-line results from its Phase 2 VALIANT trial for verekitug, a treatment for severe asthma, on Wednesday at 8:00 a.m. ET. The 478-patient trial evaluated the safety and efficacy of verekitug, an antagonist targeting the TSLP receptor. This announcement follows an initiation of coverage by Mizuho with an Outperform rating and a $51.00 price target, expressing confidence in verekitug's potential.
Upstream Bio to Host Webcast to Report Top-Line Results
Upstream Bio will host a webcast on February 11, 2026, at 8:00 a.m. ET to announce top-line results from its Phase 2 VALIANT trial of verekitug for severe asthma. Verekitug is an antagonist targeting the TSLP receptor, and the trial involved 478 patients over 24 to 60 weeks. The webcast will be accessible via the company's investors section.
Upstream Bio to reveal Phase 2 trial results for asthma drug
Upstream Bio is set to announce the top-line results of its Phase 2 VALIANT trial for verekitug, a drug developed to treat severe asthma. The pharmaceutical company has scheduled a webcast for tomorrow morning at 8:00 a.m. ET to release these results. This event is a significant step in their efforts to advance treatment options for asthma sufferers.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Consensus Rating of "Moderate Buy" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received a consensus "Moderate Buy" rating from five analysts, with an average 12-month price target of $45.25. The company's shares opened at $26 and were down about 11.5%, trading within a 1-year range of $5.14–$33.68. Institutional investors, including Vanguard and UBS, have recently increased their holdings in the biotechnology company.
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and BillionToOne, Inc. Class A (BLLN)
This article highlights bullish analyst sentiments for two healthcare companies: Upstream Bio, Inc. (UPB) and BillionToOne, Inc. Class A (BLLN). Matt Phipps from William Blair maintained a Buy rating on Upstream Bio with a $48.80 average price target, while Subbu Nambi from Guggenheim maintained a Buy rating on BillionToOne with a $120.00 price target. Both companies received a Strong Buy analyst consensus rating.
Upstream Bio, Inc. (UPB) Stock Analysis: Potential 49.64% Upside Amid Strong Buy Ratings
Upstream Bio, Inc. (UPB), a clinical-stage biotech company focused on inflammatory diseases, shows a promising outlook with significant analyst interest. Despite currently lacking positive earnings and traditional valuation metrics, its drug verekitug in advanced trials and a 12.50% revenue growth rate suggest future potential. Analysts overwhelmingly recommend a "buy" rating, projecting an average target price of $47.57, indicating a 49.64% upside, although investors should be aware of the inherent risks of biotech investments.
Why Upstream Bio (UPB) Is Up 12.2% After JPM Debut And VALINAT Hopes
Upstream Bio (UPB) saw a 12.2% stock increase following its presentation at the J.P. Morgan Healthcare Conference and renewed analyst coverage of its asthma candidate, verekitug. The market is keenly focused on the upcoming Phase 2 VALINAT readout, which is a major driver of investor sentiment despite the company's current unprofitability and substantial cash burn. Investors are weighing strong physician interest against the company's early-stage pipeline and existing valuation concerns.
Upstream Bio stock hits all-time high at 33.05 USD By Investing.com
Upstream Bio's stock reached an all-time high of $33.05 USD, reflecting a 171.67% increase over the past year due to strong performance and investor confidence. Several investment firms, including Mizuho, Piper Sandler, and Truist Securities, have initiated or reiterated positive ratings for the company, largely due to the potential of its lead asthma treatment, verekitug, ahead of anticipated Phase II results. The stock's surge highlights the company's successful strategies and market presence.
Upstream Bio stock hits all-time high at 33.05 USD By Investing.com
Upstream Bio Inc.'s stock reached an all-time high of $33.05, representing a 171.67% increase over the past year, driven by strong investor confidence and successful strategies. This surge follows positive attention from investment firms like Mizuho, Piper Sandler, and Truist Securities, which have issued "Outperform" or "Buy" ratings based on the potential of its lead asthma treatment, verekitug, and promising Phase 2 trial results. The company's growth trajectory and market opportunities have positioned it as a significant player in the industry.
Positioning Upstream Bio for Commercial Success: Buy Rating on UPB Driven by Physician Enthusiasm and Long-Acting TSLP Opportunity Ahead of VALINAT Readout
LifeSci Capital analyst Kate Dellorusso initiated a Buy rating on Upstream Bio (UPB), citing strong commercial potential for its drug verekitug in asthma. The rating is based on high physician enthusiasm for TSLP inhibition and long-acting treatments, supported by Tezspire's success, and the upcoming Phase 2 VALINAT readout. Dellorusso suggests that achieving Tezspire-like efficacy at 12-week dosing or credible efficacy at 24-week dosing would drive significant uptake for verekitug.
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts
Upstream Bio, Inc. (NASDAQ:UPB) has received a "Moderate Buy" consensus rating from five analysts, with an average one-year price target of $45.25. The company's stock opened at $29.75, has a market capitalization of $1.61 billion, and recently beat its quarterly EPS estimate. Several institutional investors have also increased their stakes in the company.
Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Time to Buy?
Upstream Bio's stock (NASDAQ:UPB) surged 7.8% to $27.88, despite trading volume being 63% below its daily average. Analysts hold a "Moderate Buy" consensus with an average price target of $45.25, though the clinical-stage biotech remains unprofitable, reporting an EPS of -$0.63 last quarter and a projected -4.3 EPS for the current fiscal year. Recent analyst ratings include "Strong Buy" and "Outperform."
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio announced that its CEO, Rand Sutherland, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT. A live webcast and replay of the presentation will be available on the Investors section of the company's website. Upstream Bio is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases using verekitug, an antagonist targeting the TSLP receptor.
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio, a clinical-stage biotechnology company, announced that its CEO, Rand Sutherland, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company is developing verekitug, an antagonist targeting the TSLP receptor for inflammatory diseases like chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease. A live webcast and replay of the presentation will be available on the company's website.
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio's CEO, Rand Sutherland, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT. The company, focused on inflammatory diseases, will discuss its clinical-stage treatments, including verekitug for severe respiratory disorders, which targets the TSLP receptor. A live webcast and replay will be available on Upstream Bio's investor relations website.
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio will present at the 44th Annual J.P. Morgan Healthcare Conference, with CEO Rand Sutherland speaking on January 12, 2026, at 2:15 p.m. PT. A webcast and replay will be available on the company's investor relations website. Upstream Bio is a clinical-stage biotechnology company focused on treating inflammatory diseases, particularly severe respiratory disorders, with its drug verekitug.
Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
Upstream Bio's CEO, Rand Sutherland, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. PT. A live webcast of the presentation will be available on the Investors section of Upstream Bio’s website. The company is a clinical-stage biotechnology firm focused on developing treatments for inflammatory diseases, specifically severe respiratory disorders, with its lead candidate verekitug.
Upstream Bio (NASDAQ:UPB) Stock Price Up 4.8% - Should You Buy?
Upstream Bio (NASDAQ:UPB) saw its stock price rise by 4.8% to $30.61, trading with significantly lower volume than its daily average. The clinical-stage biotech company, with a $1.65 billion market cap, has an average analyst rating of "Moderate Buy" and a price target of $45.25, despite reporting a loss per share for the quarter. Several hedge funds have also adjusted their positions in the company, increasing their holdings.
Does Mizuho’s New Coverage of Upstream Bio (UPB) Reframe the Stock’s Risk‑Reward Narrative?
Mizuho Securities analyst Joseph Catanzaro initiated coverage on Upstream Bio (UPB) with a buy rating and a US$51 target, drawing new attention to the biotech company. While this adds another data point to the stock's valuation, the article emphasizes that the core investment narrative, relying on clinical success of verekitug and addressing significant losses, remains unchanged. Investors should consider upcoming clinical readouts, potential dilution, and varied fair value estimates before making investment decisions.
Upstream Bio (NASDAQ:UPB) Stock Rating Upgraded by Mizuho
Mizuho has upgraded Upstream Bio (NASDAQ:UPB) to a "strong-buy" rating. This upgrade contributes to a "Moderate Buy" consensus rating for the company, with an average price target of $45.25 from analysts. Upstream Bio recently beat earnings estimates in its last quarter, reporting ($0.63) EPS against an expected ($0.78), and revenue of $0.68 million compared to $0.65 million.
Upstream Bio initiated with an Outperform at Mizuho
Mizuho analyst Joseph Catanzaro initiated coverage of Upstream Bio (UPB) with an Outperform rating and a $51 price target. The analyst anticipates a positive Phase II readout for Upstream Bio's lead program, verekitug, in asthma during Q1, projecting $2.7 billion in risk-adjusted worldwide sales by 2035. This positive data is expected to drive stock outperformance for the company.
Bain Capital Life Sciences Investors LLC Raises Holdings in Upstream Bio, Inc. $UPB
Bain Capital Life Sciences Investors LLC has increased its stake in Upstream Bio, Inc. (NASDAQ:UPB) by 6.3% during the second quarter, now owning 2,439,538 shares worth $26.79 million. Other institutional investors have also adjusted their holdings in the company. Upstream Bio has received mixed analyst ratings with an average "Moderate Buy" and a consensus price target of $43.33, while the company reported better-than-expected earnings for the last quarter.
Geode Capital Management LLC Buys 235,958 Shares of Upstream Bio, Inc. $UPB
Geode Capital Management LLC significantly increased its stake in Upstream Bio, Inc. (NASDAQ:UPB) during the second quarter, purchasing an additional 235,958 shares and now owning 1.20% of the company, valued at $7.10 million. Despite the company remaining unprofitable with negative margins, analysts have a "Moderate Buy" consensus rating and a price target of $43.33. Upstream Bio, a clinical-stage biotechnology company focused on inflammatory diseases, recently reported earnings that beat consensus estimates.
Lifesci Capital Forecasts Upstream Bio FY2025 Earnings
Lifesci Capital analysts have issued their FY2025 earnings estimates for Upstream Bio (NASDAQ:UPB), forecasting a loss of ($2.55) per share and setting an "Outperform" rating with a $43.00 target price. This projection is significantly more optimistic than the consensus full-year loss of ($4.30) per share. Upstream Bio recently beat quarterly estimates, reporting ($0.63) EPS and $0.68 million in revenue, while analyst ratings for the company are generally positive with an average "Moderate Buy" rating and a target price of $43.33.
Upstream Bio initiated with an Outperform at LifeSci Capital
LifeSci Capital has initiated coverage on Upstream Bio (UPB) with an Outperform rating and a $43 price target. This information was first published by TheFly. The company has recently seen positive developments, including clinical advancements for Verekitug and similar "Outperform" ratings from other analysts.
